Skip to main content
  • Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.
Elizabeth M. Whitehorn, Director

Provider Notice Issued 12/08/2022

Date:   December 8, 2022

To:       All Medical Assistance Program Providers      

Re:      Confirmation of No Copayment for Naloxone Effective January 1, 2023, per Public Act 102-1038

___________________________________________________________________________________________________________________________________________________

This notice confirms the Department of Healthcare and Family Services (HFS) will not charge a customer copayment for Naloxone pursuant to Public Act 102-1038. This applies to customers covered under HFS' fee-for-service (FFS) program and the managed care organization (MCO) plans.

The Act states that HFS shall not impose a copayment on the coverage provided for Naloxone Hydrochloride under the Medical Assistance program. This notice verifies that pharmacies dispensing Naloxone will not charge a drug copayment for this medication under any of HFS' Medical Programs.

Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565 for FFS claims, or the applicable MCO plan.

 
Kelly Cunningham, Administrator
Division of Medical Programs